10,415 Shares of Zimmer Biomet Holdings, Inc. $ZBH Acquired by Associated Banc Corp

Key Points

• Associated Banc Corp acquired 10,415 Zimmer Biomet shares in the third quarter, valued at approximately $925,000. Institutional investors collectively own 88.89% of the company’s stock.
• Zimmer Biomet’s latest quarterly results slightly beat estimates: adjusted EPS was $1.90 versus $1.88 expected, and revenue of $2.06 billion rose 3.1% year over year. The company also raised its 2026 outlook, though weak knee sales and margin pressure remain challenges.
• Analyst sentiment is mostly cautious: the consensus rating is “Hold,” with an average price target of $105.68. Seven analysts rate the stock a Buy, 16 a Hold, and one a Sell.

Associated Banc Corp bought a new stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 10,415 shares of the medical equipment provider's stock, valued at approximately $925,000.

Other large investors have also recently made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Zimmer Biomet during the third quarter valued at about $4,628,000. ProShare Advisors LLC lifted its stake in shares of Zimmer Biomet by 11.5% in the 3rd quarter. ProShare Advisors LLC now owns 41,337 shares of the medical equipment provider's stock valued at $3,672,000 after acquiring an additional 4,249 shares during the last quarter. Vise Technologies Inc. bought a new stake in shares of Zimmer Biomet in the 3rd quarter valued at about $268,000. Grandfield & Dodd LLC grew its holdings in shares of Zimmer Biomet by 80.5% in the third quarter. Grandfield & Dodd LLC now owns 20,823 shares of the medical equipment provider's stock worth $1,818,000 after purchasing an additional 9,284 shares during the last quarter. Finally, Cidel Asset Management Inc. purchased a new stake in shares of Zimmer Biomet during the third quarter worth about $207,000. 88.89% of the stock is owned by hedge funds and other institutional investors.

Zimmer Biomet Trading Up 12.8%

NYSE:ZBH opened at $109.46 on Thursday. The stock has a market cap of $20.88 billion, a price-to-earnings ratio of 26.63, a PEG ratio of 2.33 and a beta of 0.50. The company has a quick ratio of 0.94, a current ratio of 1.69 and a debt-to-equity ratio of 0.50. The company's 50 day moving average price is $94.90 and its 200-day moving average price is $91.89. Zimmer Biomet Holdings, Inc. has a 52 week low of $79.12 and a 52 week high of $112.55.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last released its quarterly earnings data on Wednesday, November 4th. The medical equipment provider reported $1.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.88 by $0.02. The business had revenue of $2.06 billion for the quarter, compared to analysts' expectations of $2.04 billion. Zimmer Biomet had a return on equity of 13.12% and a net margin of 9.48%. The firm's quarterly revenue was up 3.1% on a year-over-year basis. During the same period in the prior year, the firm posted $1.90 EPS. On average, equities research analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.54 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, October 30th. Investors of record on Wednesday, September 30th were issued a $0.24 dividend. This represents a $0.96 annualized dividend and a yield of 0.9%. The ex-dividend date was Wednesday, September 30th. Zimmer Biomet's dividend payout ratio (DPR) is presently 23.36%.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on ZBH shares. Truist Financial boosted their price target on shares of Zimmer Biomet from $92.00 to $106.00 and gave the company a "hold" rating in a research report on Thursday, August 6th. Argus reissued a "buy" rating and issued a $125.00 price target on shares of Zimmer Biomet in a research report on Thursday, October 22nd. Royal Bank Of Canada lifted their price objective on Zimmer Biomet from $101.00 to $110.00 and gave the company an "outperform" rating in a research note on Thursday, August 6th. Barclays raised Zimmer Biomet to a "hold" rating in a report on Wednesday, October 7th. Finally, Wall Street Zen raised Zimmer Biomet from a "hold" rating to a "buy" rating in a research note on Saturday, October 31st. Seven analysts have rated the stock with a Buy rating, sixteen have given a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Hold" and a consensus target price of $105.68.

Key Headlines Impacting Zimmer Biomet

Here are the key news stories impacting Zimmer Biomet this week:

• Positive Sentiment: Adjusted Q3 earnings were $1.90 per share, ahead of analyst expectations, while revenue of $2.063 billion also beat estimates and increased 3.1% year over year. Zimmer Biomet Announces Third Quarter 2026 Financial Results
• Positive Sentiment: Zimmer Biomet lifted its 2026 financial outlook. Strong hip and S.E.T. sales helped offset weaker knee performance, supporting the view that its product diversification is helping sustain growth. Zimmer Biomet Lifts Annual Growth Despite Challenging Knee Market
• Positive Sentiment: The CEO said the company is not seeing a slowdown in orthopedic procedures, a reassuring demand signal for its core market. Zimmer Biomet CEO doesn’t see slowdown in ortho procedures
• Negative Sentiment: Underlying challenges remain: knee sales were weak and margin pressure weighed on results. GAAP diluted EPS fell 13.8% to $1.00, while adjusted EPS of $1.90 was unchanged from a year earlier. Zimmer Biomet Q3 2026: How Diversification Offset a Weak Knee Quarter

Insider Buying and Selling

In other Zimmer Biomet news, insider Kevin R. Thornal sold 5,691 shares of the business's stock in a transaction on Friday, September 11th. The shares were sold at an average price of $92.95, for a total transaction of $528,978.45. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Chad Phipps sold 3,000 shares of the firm's stock in a transaction on Friday, September 4th. The stock was sold at an average price of $98.35, for a total value of $295,050.00. Following the completion of the transaction, the insider owned 65,231 shares in the company, valued at approximately $6,415,468.85. This trade represents a 4.40% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 1.28% of the company's stock.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc is a medical technology company that develops and manufactures products used in orthopedic surgery and musculoskeletal care. Its portfolio includes implants for the hip, knee, shoulder, and other joints, as well as products for sports medicine, extremity reconstruction, trauma, and spine procedures.

The company also offers surgical technologies and solutions designed to support orthopedic procedures, including robotic-assisted surgery systems, digital tools, patient-specific planning, and related instruments.

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.